Peptide 19-2.5 inhibits heparan sulfate-triggered inflammation in murine cardiomyocytes stimulated with human sepsis serum

• Published in: PloS one 2015-05, Vol.10 (5), p.e0127584
• Main Authors: Martin, Lukas, Schmitz, Susanne, De Santis, Rebecca, Doemming, Sabine, Haase, Hajo, Hoeger, Janine, Heinbockel, Lena, Brandenburg, Klaus, Marx, Gernot, Schuerholz, Tobias
• Format: Article
• Language: English
• Subjects: Aged; Animals; Antimicrobial Cationic Peptides - chemical synthesis; Antimicrobial Cationic Peptides - chemistry; Antimicrobial Cationic Peptides - pharmacology; Biophysics; Cardiomyocytes; Care and treatment; Cascades; Cell culture; Cell Line; Cytokines; Development and progression; Female; Hazards; Heparan sulfate; Heparitin Sulfate - toxicity; Hospitals; Humans; Inflammation; Inflammation - chemically induced; Inflammation - drug therapy; Inflammation - metabolism; Inflammation - pathology; Inflammatory response; Intensive care; Ligands; Male; Mice; Middle Aged; Myocytes, Cardiac; Neutralization; Patient outcomes; Patients; Peptides; Proteins; Risk factors; Rodents; Sepsis; Sepsis - blood; Septic shock; Serum; Sulfates; Tumor necrosis factor-TNF
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0127584

Myocardial dysfunction in sepsis has been linked to inflammation caused by pathogen-associated molecular patterns (PAMPs) as well as by host danger-associated molecular patterns (DAMPs). These include soluble heparan sulfate (HS), which triggers the devastating consequences of the pro-inflammatory cascades in severe sepsis and septic shock. Thus, there is increasing interest in the development of anti-infective agents, with effectiveness against both PAMPs and DAMPs. We hypothesized that a synthetic antimicrobial peptide (peptide 19-2.5) inhibits inflammatory response in murine cardiomyocytes (HL-1 cells) stimulated with PAMPs, DAMPs or serum from patients with septic shock by reduction and/or neutralization of soluble HS. In the current study, our data indicate that the treatment with peptide 19-2.5 decreases the inflammatory response in HL-1 cells stimulated with either PAMPs or DAMPs. Furthermore, our work shows that soluble HS in serum from patients with Gram-negative or Gram-positive septic shock induces a strong pro-inflammatory response in HL-1 cells, which can be effectively blocked by peptide 19-2.5. Based on these findings, peptide 19-2.5 is a novel anti-inflammatory agent interacting with both PAMPs and DAMPs, suggesting peptide 19-2.5 may have the potential for further development as a broad-spectrum anti-inflammatory agent in sepsis-induced myocardial inflammation and dysfunction.